SAHA treatment overcomes the anti-apoptotic effects of Bcl-2 and is associated with the formation of mature PML nuclear bodies in human leukemic U937 cells

Chemico-Biological Interactions

Volumn 181, Issue 1, 2009, Pages 61-70

  Lee, Jee Suk ^a   Jeong, Seung Hun ^a   Soung, Young Hwa ^a   Kim, Tae Hyun ^a   Choi, Hong Jo ^a   Park, Bong Soo ^b   Kwon, Taeg Kyu ^c   Yoo, Young Hyun ^a  

^a Dong A University College of Medicine   (South Korea)

^b Pusan National University   (South Korea)

^c Keimyung University   (South Korea)

Author keywords

Apoptosis; Bcl 2; Leukemia; PML; SAHA

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN BCL 2; RESVERATROL; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL NUCLEUS INCLUSION BODY; CELL STRAIN U937; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION;

APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYDROXAMIC ACIDS; INTRANUCLEAR INCLUSION BODIES; LEUKEMIA; MEMBRANE POTENTIALS; MICROSCOPY, CONFOCAL; PROTO-ONCOGENE PROTEINS C-BCL-2; U937 CELLS;

EID: 67650879015     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.02.007     Document Type: Article

References (39)

1. Schimmer A.D., Hedley D.W., Penn L.Z., and Minden M.D. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood 98 (2001) 3541-3553
2. Lowenberg B., Downing J.R., and Burnett A. Acute myeloid leukemia. N. Engl. J. Med. 341 (1999) 1051-1062
3. Smith M., Barnett M., Bassan R., Gatta G., Tondini C., and Kern W. Adult acute myeloid leukaemia. Crit. Rev. Oncol. Hematol. 50 (2004) 197-222
4. Dasmahapatra G., Almenara J.A., and Grant S. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2. Mol. Pharmacol. 69 (2006) 288-298
5. Tsujimoto Y., and Croce C.M. Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 5214-5218
6. Kluck R.M., Bossy-Wetzel E., Green D.R., and Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275 (1997) 1132-1136
7. Murph A.N., Bredesen D.N., Cortopassi G., Wang E., and Fiskum G. Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 9893-9898
8. Campos L., Rouault J.P., Sabido O., Oriol P., Roubi N., Vasselon C., Archimbaud E., Magaud J.P., and Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81 (1993) 3091-3096
9. Yin D.X., and Schimke R.T. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res. 55 (1995) 4922-4928
10. Park J.W., Choi Y.J., Suh S.I., Baek W.K., Suh M.H., Jin I.N., Min D.S., Woo J.H., Chang J.S., Passaniti A., Lee Y.H., and Kwon T.K. Bcl-2 overexpression attenuates resveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 activity. Carcinogenesis 22 (2001) 1633-1639
11. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92 (2000) 1210-1216
12. Lee D.Y., Hayes J.J., Pruss D., and Wolffe A.P.A. Positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 72 (1993) 73-84
13. Kim Y.K., Seo D.W., Kang D.W., Lee H.Y., Han H.W., and Kim S.N. Involvement of HDAC1 and the PI3K/PKC signaling pathways in NF-kappaB activation by the HDAC inhibitor apicidin. Biochem. Biophys. Res. Commun. 347 (2006) 1088-1093
14. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6 (2006) 38-51
15. Vigushin D.M., Ali S., Pace P.E., Mirsaidi N., Ito K., Adcock I., and Coombes R.C. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7 (2001) 971-976
16. Marks P.A., Richon V.M., Miller T., and Kelly W.K. Histone deacetylase inhibitors. Adv. Cancer Res. 91 (2004) 137-168
17. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., Smyth M.J., and Johnstone R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 10833-10838
18. Almenara J., Rosato R., and Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16 (2002) 1331-1343
19. Duan H., Heckman C.A., and Boxer L.M. Histone deacetylase inhibitors downregulate Bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol. Cell Biol. 25 (2005) 1608-1619
20. Hofmann T.G., and Will H. Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ. 10 (2003) 1290-1299
21. Spector D.L. Nuclear domains. J. Cell Sci. 114 (2001) 2891-2893
22. Muratani M., Gerlich D., Janicki S.M., Gebhard M., Eils R., and Spector D.L. Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus. Nat. Cell Biol. 4 (2002) 106-110
23. Chelbi-Alix M.K., Pelicano L., Quignon F., Koken M.H., Venturini L., Stadler M., Pavlovic J., Degos L., de, and Thé H. Induction of the PML protein by interferons in normal and APL cells. Leukemia 9 (1995) 2027-2033
24. Kakizuka A., Miller Jr. W.H., Umesono K., Warrell Jr. R.P., Frankel S.R., Murty V.V., Dmitrovsky E., and Evans R.M. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66 (1991) 663-674
25. Bernardi R., and Pandolfi P.P. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 22 (2003) 9048-9057
26. Salomoni P., and Pandolfi P.P. The role of PML in tumor suppression. Cell 108 (2002) 165-170
27. Pearson M., and Pelicci P.G. PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene 20 (2001) 7250-7256
28. Negorev D., and Maul G.G. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 20 (2001) 7234-7242
29. Li H., and Chen J.D. PML and the oncogenic nuclear domains in regulating transcriptional repression. Curr. Opin. Cell Biol. 12 (2000) 641-644
30. Zhong S., Müller S., Ronchetti S., Freemont P.S., Dejean A., and Pandolfi P.P. Role of SUMO-1-modified PML in nuclear body formation. Blood 95 (2000) 2748-2752
31. Lehembre F., Muller S., Pandolfi P.P., and Dejean A. Regulation of Pax3 transcriptional activity by SUMO-1-modified PML. Oncogene 20 (2001) 1-9
32. Son S.H., Yu E., Ahn Y., Choi E.K., Lee H., and Choi J. Retinoic acid attenuates promyelocytic leukemia protein-induced cell death in breast cancer cells by activation of the ubiquitin-proteasome pathway. Cancer Lett. 247 (2007) 213-223
33. Fogal V., Gostissa M., Sandy P., Zacchi P., Sternsdorf T., and Jensen K. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19 (2000) 6185-6195
34. Bode A.M., and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4 (2004) 793-805
35. Pearson M. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406 (2000) 207-210
36. 3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193 (2001) 1361-1372
37. LaMorte V.J., Dyck J.A., Ochs R.L., and Evans R.M. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 4991-4996
38. Zhu J., Koken M.H., Quignon F., Chelbi-Alix M.K., Degos L., Wang Z.Y., Chen Z., de, and Thé H. Arsenic induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 3978-3983
39. Gongora R., Stephan R.P., Zhang Z., and Cooper M.D. An essential role for Daxx in the inhibition of B lymphopoiesis by type I interferons. Immunity 14 (2001) 727-737